Patents by Inventor Philip Marks

Philip Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100310045
    Abstract: X-ray apparatus comprises a linear accelerator adapted to produce a beam of electrons at one of at least two selectable energies and being controlled to change the selected energy on a periodic basis, and a target to which the beam is directed thereby to produce a beam of x-radiation, the target being non-homogenous and being driven to move periodically in synchrony with the change of the selected energy. In this way, the target can move so that a different part is exposed to the electron beam when different pulses arrive. This enables the appropriate target material to be employed depending on the selected energy. The easiest form of periodic movement for the target is likely to be a rotational movement. The target can be immersed in a coolant fluid such as water. The linear accelerator can be of the type disclosed in WO2006/097697A1. The target preferably contains at least one exposed area of tungsten and/or at least one exposed area of carbon.
    Type: Application
    Filed: December 21, 2007
    Publication date: December 9, 2010
    Applicants: ELEKTA AB (PUBL), THE INSTITUTE OF CANCER RESEARCH
    Inventors: Kevin John Brown, Maria Giulia Thompspm, Vibeke Nordmark Hansen, Philip Mark Evans, David Anthony Roberts
  • Patent number: 7807240
    Abstract: A multilayer white polymeric film having a core layer with an optical transmission density greater than 2.0, a white polyester outer layer on either side of the core layer and an ink receptive layer on the outer surface of the white polyester layers.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: October 5, 2010
    Assignee: DuPont Teijin Films U.S. Limited Partnership
    Inventors: John Francis, Philip Mark Rutter
  • Publication number: 20100247509
    Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.
    Type: Application
    Filed: December 1, 2005
    Publication date: September 30, 2010
    Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
  • Patent number: 7799835
    Abstract: The present invention provides, e.g., methods to recycle and/or reduce plastic, non-plastic, or a combination thereof, from a waste stream. The methods of the present invention include contacting the plastic waste with infrared (IR) energy at one or more frequencies and at one or more intensities, over a period of time effective to heat plastic present in the plastic waste.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: September 21, 2010
    Assignee: Next-Tec, Ltd.
    Inventors: Peter Anthony Smith, Adam J. Koffler, Philip Mark Smith
  • Publication number: 20100209248
    Abstract: A system for the structural monitoring of blades 1 on a wind turbine. Each blade 1 has respective optical fibre bragg grating sensors 5. The system has a number of input connectors, which connect to the strain sensors 5 of respective blades 1. A single output connector connects to a data processing device 3 which processes signals from the strain sensors 5. The input connectors each have a signal path to the output connector that is different in length to the signal path from the other input connectors, such that signals from a given blade 1 can be identified at the data processing device 3 by the time of arrival of the signals. The system has the advantage that the each of the blades 1, including the sensors attached to it or embedded within it can be identical and therefore interchangeable.
    Type: Application
    Filed: August 20, 2007
    Publication date: August 19, 2010
    Inventors: Mark Volanthen, Philip Mark Rhead, Martin Peter William Jones, Glynn David Lloyd
  • Patent number: 7691923
    Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of strong base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: April 6, 2010
    Assignee: Rohm and Haas Company
    Inventors: Eric Gustave Lundquist, Allen Philip Marks
  • Patent number: 7687555
    Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of weak base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: March 30, 2010
    Assignee: Rohm and Haas Company
    Inventors: Eric Gustave Lundquist, Allen Philip Marks
  • Patent number: 7674470
    Abstract: Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain HN portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated HC thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell sur
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: March 9, 2010
    Assignees: Health Protection Agency, Syntaxin Limited
    Inventors: Charles Clifford Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
  • Publication number: 20100034802
    Abstract: Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.
    Type: Application
    Filed: June 1, 2007
    Publication date: February 11, 2010
    Applicants: SYNTAXIN LIMITED, ALLERGAN, INC.
    Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, K. Roger Aoki, Joseph Francis, Lance Steward
  • Patent number: 7659092
    Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: February 9, 2010
    Assignees: Syntaxin, Ltd., Allergan, Inc.
    Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
  • Publication number: 20100022751
    Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.
    Type: Application
    Filed: February 11, 2009
    Publication date: January 28, 2010
    Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCY
    Inventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
  • Patent number: 7640130
    Abstract: Systems and methods for effectuating verification and certification of verifiable devices. Preferably, but not necessarily, such certification occurs or is communicated remotely. A verifiable device may be directly or indirectly connected to an appropriate regulatory agency through a communication mechanism. One or more tests may be performed on the verifiable device to verify that the device is functioning properly. The test results are directly or indirectly transmitted to the regulatory agency. If the tests were passed then the verifiable device may be approved for use. When self-certification or remote certification is provided for, the need for in-person verification and certification procedures by agency personnel may be eliminated.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: December 29, 2009
    Assignee: Mettler-Toledo, Inc.
    Inventors: John Scott Churan, Philip Mark Metzler
  • Publication number: 20090274708
    Abstract: Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain HN portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated HC thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell sur
    Type: Application
    Filed: March 6, 2009
    Publication date: November 5, 2009
    Applicants: Health Protection Agency, Syntaxin Limited
    Inventors: Charles Clifford SHONE, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
  • Publication number: 20090246827
    Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.
    Type: Application
    Filed: July 17, 2008
    Publication date: October 1, 2009
    Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCY
    Inventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
  • Publication number: 20090148888
    Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.
    Type: Application
    Filed: January 27, 2009
    Publication date: June 11, 2009
    Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCY
    Inventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
  • Publication number: 20090035822
    Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 5, 2009
    Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
  • Publication number: 20090004174
    Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.
    Type: Application
    Filed: December 1, 2005
    Publication date: January 1, 2009
    Applicant: SYNTAXIN LIMITED
    Inventors: Keith Alan Foster, John Chaddock, Philip Marks, Patrick Stancombe, Lyndsey Durose
  • Publication number: 20080287571
    Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of weak base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.
    Type: Application
    Filed: May 1, 2008
    Publication date: November 20, 2008
    Inventors: Eric Gustave Lundquist, Allen Philip Marks
  • Publication number: 20080287572
    Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of strong base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.
    Type: Application
    Filed: May 1, 2008
    Publication date: November 20, 2008
    Inventors: Eric Gustave Lundquist, Allen Philip Marks
  • Patent number: D625977
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: October 26, 2010
    Assignee: Vertex Stone and Chinaware Ltd.
    Inventors: Brian John Watson, Anthony Arthur Wills, Philip Mark Hall